On February 27, 2020, a subsidiary of Generex, NuGenerex Immuno-Oncology, announced that it had begun a vaccine project with the goal of creating an Ii-Key peptide-based vaccine against COVID-19.
Tarehe 27 Februari 2020, kampuni tanzu ya Generex, NuGenerex Immuno-Oncology, ilitangaza kuwa walikuwa wanaanza mradi wa chanjo wa kuunda chanjo ya Ii-Key peptide ya kuzuia COVID-19.